Acetylsalicylic acid (ASA) is a well-established
drug for
heart attack and
stroke prophylaxis. Furthermore, numerous studies have reported an
anti-carcinogenic effect, but its exact mechanism is still unknown. Here, we applied VEGFR-2-targeted molecular ultrasound to explore a potential inhibitory effect of ASA on
tumor angiogenesis in vivo. Daily ASA or placebo
therapy was performed in a 4T1
tumor mouse model. During
therapy, ultrasound scans were performed using nonspecific
microbubbles (CEUS) to determine the relative intratumoral blood volume (rBV) and VEGFR-2-targeted
microbubbles to assess angiogenesis. Finally, vessel density and
VEGFR-2 expression were assessed histologically. CEUS indicated a decreasing rBV in both groups over time.
VEGFR-2 expression increased in both groups up to Day 7. Towards Day 11, the binding of VEGFR-2-specific
microbubbles further increased in controls, but significantly (p = 0.0015) decreased under ASA
therapy (2.24 ± 0.46 au vs. 0.54 ± 0.55 au). Immunofluorescence showed a tendency towards lower vessel density under ASA and confirmed the result of molecular ultrasound. Molecular US demonstrated an inhibitory effect of ASA on
VEGFR-2 expression accompanied by a tendency towards lower vessel density. Thus, this study suggests the inhibition of angiogenesis via
VEGFR-2 downregulation as one of the anti-
tumor effects of ASA.